These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35831669)

  • 1. Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020.
    Sørensen AMS; Wesselhöeft R; Andersen JH; Reutfors J; Cesta CE; Furu K; Hartz I; Rasmussen L
    Eur Child Adolesc Psychiatry; 2023 Oct; 32(10):2049-2056. PubMed ID: 35831669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of Stimulants and Atomoxetine for Attention-Deficit/Hyperactivity Disorder among 5.4 Million Children Using Population-Based Longitudinal Data.
    Furu K; Karlstad Ø; Zoega H; Martikainen JE; Bahmanyar S; Kieler H; Pottegård A
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):373-379. PubMed ID: 27911044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010-2019.
    Cohen JM; Srinivas C; Furu K; Cesta CE; Reutfors J; Karlstad Ø
    Eur J Clin Pharmacol; 2023 Jan; 79(1):173-180. PubMed ID: 36445458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries.
    Karlstad Ø; Zoëga H; Furu K; Bahmanyar S; Martikainen JE; Kieler H; Pottegård A
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1507-1514. PubMed ID: 27586399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.
    Dalsgaard S; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):432-9. PubMed ID: 24015896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR; Man KKC; Bahmanyar S; Berard A; Bilder S; Boukhris T; Bushnell G; Crystal S; Furu K; KaoYang YH; Karlstad Ø; Kieler H; Kubota K; Lai EC; Martikainen JE; Maura G; Moore N; Montero D; Nakamura H; Neumann A; Pate V; Pottegård A; Pratt NL; Roughead EE; Macias Saint-Gerons D; Stürmer T; Su CC; Zoega H; Sturkenbroom MCJM; Chan EW; Coghill D; Ip P; Wong ICK
    Lancet Psychiatry; 2018 Oct; 5(10):824-835. PubMed ID: 30220514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
    McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
    BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing patterns for attention deficit hyperactivity disorder among children and adolescents in Taiwan from 2004 to 2017.
    Liao HC; Lin FJ; Hsu CN; Gau SS; Wang CC
    J Formos Med Assoc; 2023 Jun; 122(6):514-517. PubMed ID: 36931958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical treatment of children and youths with attention-deficit/hyperactivity disorder (ADHD): a Norwegian Prescription Registry Based Study.
    Norum J; Olsen AI; Nohr FI; Heyd A; Totth A
    Glob J Health Sci; 2014 Apr; 6(4):155-62. PubMed ID: 24999151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early discontinuation of attention-deficit/hyperactivity disorder drug treatment: a Danish nationwide drug utilization study.
    Pottegård A; Bjerregaard BK; Kortegaard LS; Zoëga H
    Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):349-53. PubMed ID: 25220739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.
    Song I; Shin JY
    Epidemiol Health; 2016; 38():e2016045. PubMed ID: 27866408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of long-term ADHD medication use in Australian children.
    Efron D; Mulraney M; Sciberras E; Hiscock H; Hearps S; Coghill D
    Arch Dis Child; 2020 Jun; 105(6):593-597. PubMed ID: 31937570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
    Song I; Lee MS; Lee EK; Shin JY
    Asia Pac Psychiatry; 2018 Mar; 10(1):. PubMed ID: 28631372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Children's relative age in class and medication for attention-deficit/hyperactivity disorder. A population-based study in a health department in Spain].
    Librero J; Izquierdo-María R; García-Gil M; Peiró S
    Med Clin (Barc); 2015 Dec; 145(11):471-6. PubMed ID: 25913908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.
    Grimmsmann T; Himmel W
    Eur J Clin Pharmacol; 2021 Jan; 77(1):107-115. PubMed ID: 32803292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.